Powered by:


Dutch developer of a portable point-of-care device that accurately counts cells

This Dutch medtech company, focused on point of care diagnostic devices, has developed an automatic cell counter for thrombocytes or platelets that is able to accurately count platelet concentrations in whole blood as well as in platelet rich plasma (PRP) up to 10x baseline. The platelet counter removes the need to count thrombocytes manually and is a cost effective, small and flexible alternative to flow cytometers. The SME offers a distribution services agreement to the right partners.

Partnership(s) sought
  • Distribution services agreement
Descripción completa

Today platelets are either counted manually, which is labor-intensive and time consuming, or automatically using advanced counting devices (like flow cytometers) which requires serious investments and highly trained people resulting in high cost of operation. This Dutch SME developed an automatic platelet counter that is easy to use, accurate and lower in price compared to its automated alternatives. This point of care solution is used in smaller laboratories and point-of-care offices / clinics.

The device is intended to count the number of platelets per nanolitre in venous whole blood (in Ethylenediaminetetraacetic acid (EDTA)). The user of the device is a medical professional or a person working under the responsibility of a trained medical professional. The device is intended for a medical clinic or a doctor's office. Using the platelet counter takes four steps. The user
- takes (venous) blood from the patient.
- lyses the red blood cells in the blood sample using the Eppendorf cups prefilled with reagent from the disposable kit.
- fills the disposable counting slide and inserts the disposable slide in the platelet counter.
- starts the count with the software application from a computer and the results are shown on the screen in a couple of minutes.
A detailed report of a platelet/thrombocyte count can be visualized after a count has been completed. The detailed report contains information on overall results and details of the last platelet count, including relevant notifications. The counting report shows for each counted position a miniature picture of the count result and key information. Each count position is also shown in full detail with the possibility to export or print the count result.
The device is validated for 20-600 platelets per nanoliter (plt/nl), which covers about 90% of all applications. For platelet concentrations above 600 plt/nl another reagent dilution is required (validation for higher concentrations is pending)

The device is positioned in line with major key trends on the medical (devices) market: a shift from second line care to first line care closer to the patient / home. By having count results instantly it has the potential to enable innovations in personalised medicine, reduce health care costs and the ability to measure in (remote) locations without well-established medical infrastructure.

The device can offer quick insight in the exact platelet/thrombocyte concentration per nanoliter of whole blood or platelet rich plasma. The count is relevant for patients with bleeding disorders, blood disorders, bone marrow disorders and in certain specific cases for patients undergoing chemotherapy. It can be used for instance in maxillofacial surgery (Jaw reconstructions, sinus lifting, tooth extractions, periodontology) orthopaedic surgery (knee replacements, hip replacements, shoulder replacements, bone reconstruction) plastic surgery, wound care, sports medicine, cardiac surgery (sternum closure ? (leg) wound closure), traumatology, general surgery and eye surgery (Macular degeneration).

To extend its presence in foreign markets the Dutch SME is looking for established distributors with good contacts to laboratories and clinics for sales of the device. Also cooperation with pharmaceutical companies as companion diagnostic device is of interest. The partner is a professional organization, interested in a long-term cooperation and expected to provide feedback of the users to the Dutch company. The Dutch SME will provide training, third line technical and marketing support. The distributor should be willing to take responsibility for first line customer support. Service and maintenance will be the responsibility of the Dutch SME.

Socio buscado:

- Specific area of activity of the partner: The partners this Dutch company is looking for are small or medium sized distributors with a solid track-record and good contacts to laboratories and clinics in their region. Preferably they are already offering other point of care devices to their clients or are active in closely related markets of (blood) diagnostics, counting devices, hemostasis, regenerative medicine or pharmaceutics. Cooperation with pharmaceutical companies that want to use the platelet counter as companion diagnostic device is of interest.

Cooperation is offered in the frame of a distribution services agreement.

Advantages & innovations:

The unique selling points for this platelet counter are:
- it removes the need to count thrombocytes manually
- it is small device
- a flexible alternative to flowcytometers that are very costly and therefor usually unaffordable for smaller laboratories and point-of-care offices / clinics.
- all parts that come into contact with blood are disposable ? no contamination, no cleaning time.
- the total blood sample preparation and automatic counting is done within 15 minutes.

Development Stage:

Already on the market

Clasificado como: Medicine and Health

» Reference: platelets / thrombocytes

» More Information

« Go to Technological Watch


[13/06/2019] - Chemical upcycling - New Sabic compounds from postconsumer PET

[13/06/2019] - Marshall Aerospace and Defence turns to Stratasys technology - 3D printing of final flight parts for an innovative aircraft program

[13/06/2019] - Recycling plant in Thailand for 30,000 t/y of PE film scrap

[13/06/2019] - OCSiAl signs an agreement with the Brazilian company Skintech

This project has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement n° [310187].